Literature DB >> 31286006

Healthcare Utilization and Costs for Patients With Parkinson's Disease After Deep Brain Stimulation.

Kevin T Stroupe1,2, Bridget Smith1,3, Frances M Weaver1,2, Beverly Gonzalez1, Zhiping Huo1, Lishan Cao1, Dolores Ippolito1, Kenneth A Follett4.   

Abstract

OBJECTIVE: To compare the complications, healthcare utilization and costs following DBS or medical management for patients with Parkinson's disease (PD).
METHODS: We examined healthcare utilization and costs for up to 5 years between veterans with DBS and those with medical management for PD. Veterans who received DBS between 2007 and 2013 were matched with veterans who received medical management using propensity score approaches. Healthcare utilization and costs were obtained from national VA and Medicare data sources and compared using procedures to adjust for potential differences in length of follow-up.
RESULTS: We identified 611 veterans who had received DBS and a matched group of 611 veterans who did not undergo DBS. Among DBS patients, 59% had the electrodes and generator implanted during separate admissions. After 5 years of follow-up, average total healthcare costs, including DBS procedures and complications, were $77,131 (95% confidence interval: $66,095-$88,168; P < 0.001) higher per person for patients who received DBS ($162,489) than patients who received medical management ($85,358). In contrast, excluding the costs of the DBS procedures and complications, average total costs were not significantly different between patients who received DBS and patients who received medical management after 5 years of follow-up.
CONCLUSIONS: Healthcare costs over 5 years were higher for veterans who received DBS. These higher healthcare costs may reflect the costs of DBS procedures and any follow-up required plus greater surveillance by healthcare professionals following DBS as well as unobserved differences in the patients who received medical management or DBS.

Entities:  

Keywords:  Parkinson's; cost; deep brain stimulation

Year:  2019        PMID: 31286006      PMCID: PMC6592829          DOI: 10.1002/mdc3.12765

Source DB:  PubMed          Journal:  Mov Disord Clin Pract        ISSN: 2330-1619


  32 in total

1.  A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.

Authors:  O Rascol; D J Brooks; A D Korczyn; P P De Deyn; C E Clarke; A E Lang
Journal:  N Engl J Med       Date:  2000-05-18       Impact factor: 91.245

Review 2.  More or less?: Methods to compare VA and non-VA health care costs.

Authors:  A M Hendricks; D K Remler; M J Prashker
Journal:  Med Care       Date:  1999-04       Impact factor: 2.983

3.  On estimating medical cost and incremental cost-effectiveness ratios with censored data.

Authors:  H Zhao; L Tian
Journal:  Biometrics       Date:  2001-12       Impact factor: 2.571

4.  Value for taxpayers' dollars: what VA care would cost at medicare prices.

Authors:  Gary N Nugent; Ann Hendricks; Linda Nugent; Marta L Render
Journal:  Med Care Res Rev       Date:  2004-12       Impact factor: 3.929

Review 5.  Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes.

Authors:  Galit Kleiner-Fisman; Jan Herzog; David N Fisman; Filippo Tamma; Kelly E Lyons; Rajesh Pahwa; Anthony E Lang; Günther Deuschl
Journal:  Mov Disord       Date:  2006-06       Impact factor: 10.338

6.  Clinical and economic results of bilateral subthalamic nucleus stimulation in Parkinson's disease.

Authors:  V Fraix; J-L Houeto; C Lagrange; C Le Pen; P Krystkowiak; D Guehl; C Ardouin; M-L Welter; F Maurel; L Defebvre; A Rougier; A-L Benabid; V Mesnage; M Ligier; S Blond; P Burbaud; B Bioulac; A Destée; P Cornu; P Pollak
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-04       Impact factor: 10.154

7.  Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study Group.

Authors:  W C Koller; J T Hutton; E Tolosa; R Capilldeo
Journal:  Neurology       Date:  1999-09-22       Impact factor: 9.910

8.  Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up.

Authors:  M C Rodriguez-Oroz; J A Obeso; A E Lang; J-L Houeto; P Pollak; S Rehncrona; J Kulisevsky; A Albanese; J Volkmann; M I Hariz; N P Quinn; J D Speelman; J Guridi; I Zamarbide; A Gironell; J Molet; B Pascual-Sedano; B Pidoux; A M Bonnet; Y Agid; J Xie; A-L Benabid; A M Lozano; J Saint-Cyr; L Romito; M F Contarino; M Scerrati; V Fraix; N Van Blercom
Journal:  Brain       Date:  2005-06-23       Impact factor: 13.501

9.  Deep brain stimulation in Parkinson disease: a metaanalysis of patient outcomes.

Authors:  Frances Weaver; Kenneth Follett; Kwan Hur; Dolores Ippolito; Matthew Stern
Journal:  J Neurosurg       Date:  2005-12       Impact factor: 5.115

10.  Transition to the new race/ethnicity data collection standards in the Department of Veterans Affairs.

Authors:  Min-Woong Sohn; Huiyuan Zhang; Noreen Arnold; Kevin Stroupe; Brent C Taylor; Timothy J Wilt; Denise M Hynes
Journal:  Popul Health Metr       Date:  2006-07-06
View more
  2 in total

1.  Estimated Costs and Long-term Outcomes of Patients With High-Risk Non-Muscle-Invasive Bladder Cancer Treated With Bacillus Calmette-Guérin in the Veterans Affairs Health System.

Authors:  Stephen B Williams; Lauren E Howard; Meagan L Foster; Zachary Klaassen; Jan Sieluk; Amanda M De Hoedt; Stephen J Freedland
Journal:  JAMA Netw Open       Date:  2021-03-01

2.  Direct Medical Costs of Parkinson's Disease in Southern China: A Cross-Sectional Study Based on Health Insurance Claims Data in Guangzhou City.

Authors:  Hui Zhang; Wenjing Zhou; Donglan Zhang
Journal:  Int J Environ Res Public Health       Date:  2022-03-09       Impact factor: 3.390

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.